This article is more than 5 years old. Information may no longer be current.

Top ophthalmology news of the week

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Here are some of the top stories on Healio.com/OSN this week:

Prevent Blindness applauds vision health funding in 2018 omnibus spending bill

Prevent Blindness is lauding the 2018 omnibus spending bill passed by Congress and signed by President Donald Trump for including increased funding to two CDC vision health programs. Read more.

GSK to buy Novartis’ stake in Consumer Healthcare

GlaxoSmithKline is buying out Novartis’ 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion, the company announced. Read more.

Imprimis’ MKO Melt receives patent

The MKO Melt (midazolam, ketamine and ondansetron) is a nonopioid, IV-free sublingual formulation for sedation. Read more.

pSivida acquires Icon, rebrands as EyePoint Pharmaceuticals

Icon’s lead product candidate Dexycu (dexamethasone intraocular suspension 9%), a long-acting intraocular product approved for postoperative inflammation, was approved by the FDA on Feb. 9. Read more.

Visual benefits of Luxturna maintained regardless of age at treatment

Arlene V. Drack, MD, reported on the 3-year results of a phase 3 trial of Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics) in RPE65 mutation-associated inherited retinal disease undertaken at Children’s Hospital of Philadelphia and University of Iowa. Read more.